Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma
Status:
Completed
Trial end date:
2020-12-03
Target enrollment:
Participant gender:
Summary
This is an open-label, integrated, Phase 1b/2 trial to determine the recommended Phase 2 dose
(RP2D) and to evaluate the efficacy, safety, and pharmacokinetic of MSC2156119J as first-line
treatment versus sorafenib in subjects with MET+, Barcelona Clinic Liver Cancer (BCLC) Stage
C, systemic treatment naive advanced hepatocellular carcinoma (HCC) and Child-Pugh class A
liver function.